Drug repurposing finds new uses for existing drugs, saving time and money.
10 citations
,
May 2010 in “Analytica Chimica Acta” New tests detect finasteride and dutasteride in urine quickly and easily.
4 citations
,
February 2024 in “The Journal of Urology” Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.
2 citations
,
September 2025 in “Frontiers in Endocrinology” SARMs show promise but need more evidence to prove they're better than traditional androgens.
January 2025 in “International Journal of Drug Delivery Technology” A reliable method was developed to measure Finasteride and Tadalafil together, showing they degrade under certain conditions.
December 2024 in “Journal of the International Society of Sports Nutrition” Creatine monohydrate is safe and effective for muscle recovery and performance, especially for those with low creatine levels.
382 citations
,
February 2010 in “Archives of Internal Medicine” A manufacturing error in a dietary supplement caused severe selenium poisoning, affecting many people and highlighting the need for stricter quality control.
1 citations
,
August 2025 in “Clinica Chimica Acta” 10 citations
,
August 2024 in “Neuroscience & Biobehavioral Reviews” Neurosteroids may help treat disorders with too much dopamine activity.
14 citations
,
May 2005 in “Steroids” A new method was developed to make finasteride for treating hair loss.
Finasteride worsens alcohol withdrawal in female mice but eases it in male mice.
February 2023 in “Reactions Weekly”
November 2023 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
30 citations
,
January 2024 in “Frontiers in Pharmacology” These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
26 citations
,
September 2024 in “Perspectives in Clinical Research” Drug repurposing offers faster, cheaper drug development but faces challenges like safety, ethics, and funding.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
11 citations
,
August 2014 in “Current Urology Reports” Medications for enlarged prostate can cause sexual side effects like reduced libido, erectile dysfunction, and ejaculatory problems.
17 citations
,
February 2019 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” AKR1D1 controls glucocorticoid levels and receptor activity in liver cells.
August 2009 in “Australian Prescriber” Dutasteride is approved to help manage prostate enlargement.
63 citations
,
April 2017 in “Acta psychiatrica Scandinavica” Higher prenatal and adult androgen levels are linked to alcohol dependence and withdrawal severity.
February 2026 in “Pharmaceuticals” KRDQN effectively predicts adverse drug reactions with high accuracy and clear explanations.
12 citations
,
August 2006 in “American Journal of Psychiatry” Topiramate may help improve disruptive behaviors in children with bipolar disorder.
91 citations
,
July 2004 in “Journal of Biological Chemistry” Overexpressing SSAT enzyme reduces prostate tumor growth in mice.
January 2004 in “Headache” Divalproex sodium significantly improved headaches in two-thirds of patients.
November 2010 in “Clin-Alert” Monitoring for adverse effects in clinical treatments is crucial.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
September 2024 in “Journal of the American Academy of Dermatology” AH-001 could be a safer and more effective treatment for hair loss.
May 2025 in “Reactions Weekly” 24 citations
,
July 1980 in “Journal of Toxicology and Environmental Health” High doses of norethindrone acetate in rats caused various organ changes but didn't significantly increase tumor rates.